Medtronic Announces Plans to Release Data on Broad Portfolio of Cardiovascular Innovations at TCT 2008

Two-Year Data from ENDEAVOR IV, Head-to-Head Comparison of Endeavor® and Taxus® Drug-Eluting Stents, Features Prominently in Tuesday’s Late-Breaking Clinical Trials Session

MINNEAPOLIS – Medtronic, Inc. (NYSE: MDT), today announced its plans for the Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 12–17 in Washington, D.C.

Dr. Martin B. Leon, founder and chairman emeritus of the Cardiovascular Research Foundation in New York, will present two-year data from ENDEAVOR IV on Tuesday, Oct. 14, at approximately 12:15 p.m. in the Main Arena during a late-breaking clinical trials session. On staff at Columbia University Medical Center and New York-Presbyterian Hospital, Dr. Leon serves as principal investigator of ENDEAVOR IV, a head-to-head comparison of Medtronic’s Endeavor and Boston Scientific’s Taxus drug-eluting coronary stents.

Dr. Leon’s presentation will be followed by a presentation on ODESSA as part of the same session. Six-month results from ODESSA, a study that used optical coherence tomography to compare stent strut coverage in patients treated with the Endeavor, Taxus and Johnson & Johnson’s Cypher® drug-eluting stents, will be presented by Dr. Giulio Guagliumi of Ospedali Riuniti di Bergamo in Italy. Stent strut coverage relates to endothelialization.

Data on Medtronic’s broad portfolio of cardiovascular innovations will be discussed in scores of oral presentations and e-posters during TCT 2008, which marks the meeting’s 20th anniversary.

E-Posters Available Sunday Afternoon
With a few exceptions, poster presentations accepted for TCT will be available electronically Sunday afternoon, Oct. 12. These include e-posters on:

* ENDEAVOR Safety / Update to four-year pooled data analysis of ENDEAVOR clinical program on safety metrics, including death, cardiac death, myocardial infarction and stent thrombosis
* DAPT Discontinuation / Comparison of safety outcomes in Endeavor patients on dual-antiplatelet therapy for six months and 12 months
* ENDEAVOR I / Five-year results from original clinical trial (feasibility study) of Endeavor DES
* ENDEAVOR IV / Two-year outcomes of the Endeavor and Taxus drug-eluting stents in Medtronic’s largest completed randomized trial
* ENDEAVOR Five / 12-month results, including diabetic and acute myocardial infarction subsets, from international registry of patients treated with Endeavor DES in real-world clinical practice
* RESOLUTE/ Two-year results from original clinical trial (feasibility study) of Endeavor Resolute DES
* AMEthyst / Analysis of the effect of glycoprotein 2b/3a receptor inhibitor (GPI) therapy at 30 days in patients whose saphenous vein graft interventions involved embolic protection using the Interceptor Plus coronary filter

AMEthyst, a study of Medtronic’s Interceptor Plus coronary filter, is also the subject of an oral presentation on Thursday, Oct. 16 at 10:10 a.m. Dr. Srihari Naidu of the Winthrop Institute for Heart Care in upstate New York will present predictors of major adverse cardiac events (MACE) in patients whose saphenous vein grafts required subsequent percutaneous coronary intervention (PCI).

Symposia Series Starts Tuesday Morning
In the spirit of collaboration with leading clinicians worldwide that drives innovation, Medtronic is also sponsoring a series of TCT symposia that are accredited for continuing medical education (CME):

Tuesday, Oct. 14

* (7 a.m. / 07:00) “Acute and Chronic Care of the Myocardial Infarction Patient”

Wednesday, Oct. 15

* (7 a.m. / 07:00) “Optimizing Outcomes for Your Patients with Chronic Total Occlusions”
* (7 p.m. / 19:00) “Safety First: Improved DES and Anti-Platelet Treatment Strategies” (co-sponsored with Eli Lilly)

Thursday, Oct. 16

* (7 a.m. / 07:00) “Asia Pacific PCI Update”

In addition, various cardiovascular innovations from Medtronic will be featured at TCT in the meeting’s live cases from around the world and at the Medtronic booth (#826).

ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.